BioDirection Inc.
Point-of-care blood test for traumatic brain injury
This article was originally published in Start Up
Executive Summary
BioDirection Inc. is poised to launch what it says is the first objective point-of-care test for diagnosing concussion and other traumatic brain injuries. Based on proprietary nanotechnology, the company’s Tbit device detects molecular levels of two crucial brain biomarkers that are released into the bloodstream immediately after a brain injury, from just a single drop of blood in less than two minutes.
You may also be interested in...
Abbott Moves From Meeting WIC Backlog To Distributing Formula Brands To Retailers
Abbott’s US formula sales continued to fall during the October-December period on manufacturing disruptions even with production “up and running” at its Sturgis, MI, where it makes powder formula it markets under Similac, Alimentum and EleCare brands.
House Health Subcommittee Chair Prioritizes Affordability, Innovation, Ending COVID PHE
Kentucky Republican Brett Guthrie is strong proponent of health care affordability and innovation in pharmaceuticals and medical devices. He’s also monitoring FDA’s response to drug shortages and infant formula shortages.
HBW Market Executive Decisions: Sabinsa, Nutrition21, Council Of Manufacturing Association
Sabinsa founder edits selenium research book; Everwell adds Nutrition21 executives; and ACI’s Hockstad leads NAM Council of Manufacturing Associations.